FDA’s Office Of Regulatory Affairs Loses Two Top Officials, Including Chief
This article was originally published in The Gray Sheet
Executive Summary
The face of FDA's Office of Regulatory Affairs will undergo a major change as two senior leaders leave the office responsible for managing the agency's inspections and enforcement activity
You may also be interested in...
Revitalizing FDA’s Office Of Regulatory Affairs Means ‘Buying’ Some Expertise
After years of shrinking resources and workforce attrition, FDA's Office of Regulatory Affairs plans to aggressively recruit new staff to meet the emerging challenges of more complex products and overseas manufacturing
FDA Inspections Of Foreign Device Manufacturers Anemic – GAO Testimony
FDA's effectiveness in conducting device manufacturing inspections overseas was criticized by the Government Accountability Office in testimony before Congress that found overall "weaknesses" in the agency's inspection of medical device manufacturers
FDA Takes “Fresh Look” At ORA Reorg, Eyes Outsourcing Some Agency Posts
FDA's Office of Regulatory Affairs still plans to reorganize, despite its recent decision to cancel the planned closure of seven field labs